jmcwilliam@lifescicomms.com

Ashvattha Presents Positive Phase 2 Data for Subcutaneous Migaldendranib at Angiogenesis 2025 Conference

by

Multiple subcutaneous doses safe and well-tolerated   >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes   >67% reduction in anti-VEGF IVT treatment in fellow eyes of bilateral disease patients  Maintenance of BCVA and reduction of CST in these previously treated patients  Migaldendranib therapy obviates or reduces the need for more invasive in-the-eye injections  REDWOOD … Read more

Ashvattha to Present at Upcoming Angiogenesis, Exudation, and Degeneration 2025 and BIO CEO Conferences

by

REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) — Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in regions of inflammation, today announced upcoming presentations at Angiogenesis, Exudation, and Degeneration 2025 virtual meeting on February 8, 2025 and the … Read more

Ashvattha Therapeutics Announces First Patient Dosed via Subcutaneous Administration of Anti-Angiogenic Therapeutic D-4517.2 for Wet AMD and DME in Phase 2 Chronic Dosing Study

by

Open-label study will evaluate the safety and efficacy of chronic D-4517.2 dosing in patients with wet age-related macular degeneration (wet AMD) or diabetic macular edema (DME) Favorable safety and tolerability results from Phase 1 and Phase 2 single dose studies of D-4517.2 support initiation of chronic dosing study Preliminary data expected in 1H 2024   … Read more